Patrick Henno News Today

Cell-Easy SAS ("Cell-Easy"), a rapidly growing Contract Development and Manufacturing Organization ("CDMO") that specializes in cell therapy, has appointed Dr. Sebastien Ribault, PhD, to its board

TOULOUSE, France--(BUSINESS WIRE)--Cell-Easy SAS (“Cell-Easy”), a rapidly growing Contract Development and Manufacturing Organization (“CDMO”) that specializes in cell therapy, has appointed Dr. Sebastien Ribault, PhD, to its board of directors, to further accelerate its growth.Cell-Easy is a leading contract develo...

Emercell SAS (Emercell) and Cell-Easy SAS (Cell-Easy) announced today the signing of a strategic agreement for the scale-up and manufacturing of Emercell's lead product. This press release features

EPALINGES, Switzerland and MONTPELLIER, France, June 20, 2022 /PRNewswire/ -- Onward Therapeutics SA (Onward Therapeutics) and Emercell SAS (Emerc...

(1) EMERCell, a biotechnology company developing immunotherapies and cell-based therapies for oncology targets through to pharmaceutical development, announces the signature of a strategic partnership with Onward Therapeutics. The significant investment, of a confidential amount, will be made in three instalments that will allow EMERCell to reach the first human clinical trials. "We are delighted to partner with Onward Therapeutics, whose teams have recognized expertise in the development of ne...

Onward Therapeutics Makes a Strategic Investment in EMERCell for Their NK Cell Technology for Immunotherapy News provided by Share this article Share this article LAUSANNE, Switzerland, Feb. 17, 2021 /PRNewswire/ -- Onward Therapeutics SA (Onward) announced today the execution of a strategic investment in EMERCell SAS, Montpellier, France, a company that has developed a platform technology to produce off-the-shelf natural killer (NK) cells. The undisclosed amounts of the equity investment in th...